ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1753

Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint

Georgios Vasileiadis1, Anna-Karin Hultgård Ekwall2, Reshmi Sureshkumar1, Monica Guma3, Anna Rudin4, Yuan Zhang1 and Cristina Maglio1, 1Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 3San Diego VA Healthcare Service, La Jolla, CA, 4Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Meeting: ACR Convergence 2023

Keywords: Fibroblasts, Synovial, metabolomics, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Several metabolic pathways have been implicated in rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) aggressive phenotype1,2. Here, we aimed to analyse the full spectrum of metabolic alterations associated with RA by performing untargeted metabolomics using mass spectrometry in RA FLS vs. non-inflamed (NI) FLS.

Methods: Ten RA FLS were obtained from synovial tissue specimens from patients with RA undergoing joint replacement surgery. Seven NI FLS were obtained from patients with no previous history of arthritis, undergoing diagnostic arthroscopy due to previous injury that occurred over 2 months prior to the operation. We collected primary RA and NI FLS culture extracts and untargeted annotated metabolomics were performed using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (Figure 1A).

Results: Peak intensities of 138 annotated metabolites were acquired. Metabolomics analysis revealed a distinct metabolic fingerprint between RA and NI FLS as illustrated by hierarchical clustering shown as heatmap, and partial least squares – discriminant analysis (Figure 1B, C). A volcano plot combining fold change analysis and Mann-Whitney test revealed 18 metabolites having different levels in RA and NI FLS; 13 were enriched in RA FLS, while five were enriched in NI FLS (Figure 1D). Of the 13 metabolites enriched in RA FLS, 12 were acylcarnitines (Figure 1E, F).

Conclusion: RA FLS show an accumulation of acylcarnitines compared to NI FLS, which suggests an involvement of lipid metabolism in RA pathophysiology. Further studies are needed to understand this phenomenon and to determine if acylcarnitine accumulation in FLS contributes to FLS dysfunction in RA.

Supporting image 1

Figure 1: FLS metabolomics analysis. A. Experimental set up overview. B. Clustering result shown as heatmap. Distance measure using Euclidean distance, and clustering algorithm using Ward’s linkage. Samples are shown on the x axis, while metabolites are shown on the y axis. C. Partial least squares – discriminant analysis showing the 2-D scores plot between principal component 1 and 2. Each dot represents a sample. The cycles show the 95% confidence interval. D. Enriched metabolites by volcano plot defined as fold change (x) ≥1.5 and Mann-Whitney test p-value (y) <0.05. The red dots represent acylcarnitines. E. Dot plots of the peak intensities of three selected acylcarnitines and L-carnitine in NI RA FLS. Mann-Whitney test was performed. p<0.05 was signified with *, p<0.01 with **, and p<0.001 with ***. F. ROC curves of three selected acylcarnitines and L-carnitine. Sensitivity is on the y-axis, and the specificity on the x-axis. Abbreviations: RA, rheumatoid arthritis; NI, non-inflamed; FLS, fibroblast-like synoviocytes; LC-QTOF-MS, liquid chromatography coupled to quadrupole time-of-flight mass spectrometry; PLS-DA, partial least squares - discriminant analysis; AUC, area-under-the-curve.


Disclosures: G. Vasileiadis: None; A. Hultgård Ekwall: AbbVie/Abbott, 1, 2, Boehringer-Ingelheim, 6, Pfizer, 1; R. Sureshkumar: None; M. Guma: Genentech, 5, Gilead, 5, Novartis, 5, Pfizer, 5; A. Rudin: AstraZeneca, 12, financial support; Y. Zhang: None; C. Maglio: None.

To cite this abstract in AMA style:

Vasileiadis G, Hultgård Ekwall A, Sureshkumar R, Guma M, Rudin A, Zhang Y, Maglio C. Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/acylcarnitine-enrichment-is-a-characteristic-of-rheumatoid-arthritis-fibroblast-like-synoviocyte-metabolic-fingerprint/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acylcarnitine-enrichment-is-a-characteristic-of-rheumatoid-arthritis-fibroblast-like-synoviocyte-metabolic-fingerprint/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology